Multicenter, Randomized, Single-blind, Placebo-controlled, Combined 2-fold Cross-over and Group-comparison, Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Oral Doses of BAY85 3934 in Subjects With Chronic Kidney Disease (CKD)

Trial Profile

Multicenter, Randomized, Single-blind, Placebo-controlled, Combined 2-fold Cross-over and Group-comparison, Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Oral Doses of BAY85 3934 in Subjects With Chronic Kidney Disease (CKD)

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2016

At a glance

  • Drugs Molidustat (Primary)
  • Indications Kidney disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Apr 2016 Time frame for primary endpoints changed. For adverse events time frame changed from 30 days to 9 weeks, and for blood pressure time frame changed from day 1 to 9 weeks.
    • 15 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top